Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1,800,000 Profiles
- More than 3,500 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Vincent Miller
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.8 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
74
Kris, Mark
26
Heelan, Robert
24
Krug, Lee
20
Pao, William
18
Riely, Gregory
17
Grant, Stefan
17
Azzoli, Christopher
16
Seshan, Venkatraman
16
Ng, Kenneth
14
Pizzo, Barbara
13
Zakowski, Maureen
11
Tyson, Leslie
11
Rizvi, Naiyer
11
Rusch, Valerie
11
Ladanyi, Marc
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Vincent Miller (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2010: Janjigian Yelena Y; Lee Wooin; Kris Mark G; Miller Vincent A; Krug Lee M; Azzoli Christopher G; Senturk Emir; Calcutt M Wade; Rizvi Naiyer A
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Cancer chemotherapy and pharmacology 2010;65(5):833-8.
-
2009: Zakowski Maureen F; Hussain Sanaa; Pao William; Ladanyi Marc; Ginsberg Michelle S; Heelan Robert; Miller Vincent A; Rusch Valerie W; Kris Mark G
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Archives of pathology & laboratory medicine 2009;133(3):470-7.
-
2009: Glezerman I; Kris M G; Miller V; Seshan S; Flombaum C D
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Clinical nephrology 2009;71(2):130-9.
-
2009: Riely Gregory J; Rizvi Naiyer A; Kris Mark G; Milton Daniel T; Solit David B; Rosen Neal; Senturk Emir; Azzoli Christopher G; Brahmer Julie R; Sirotnak Francis M; Seshan Venkatraman E; Fogle Margaret; Ginsberg Michelle; Miller Vincent A; Rudin Charles M
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
-
2008: Bean James; Riely Gregory J; Balak Marissa; Marks Jenifer L; Ladanyi Marc; Miller Vincent A; Pao William
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7519-25.
-
2008: Riely Gregory J; Kris Mark G; Rosenbaum Daniel; Marks Jenifer; Li Allan; Chitale Dhananjay A; Nafa Khedoudja; Riedel Elyn R; Hsu Meier; Pao William; Miller Vincent A; Ladanyi Marc
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5731-4.
-
2008: Marks Jenifer L; Golas Ben; Kirchoff Tomas; Miller Vincent A; Riely Gregory J; Offit Kenneth; Pao William
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):805.
-
2008: Li Allan R; Chitale Dhananjay; Riely Gregory J; Pao William; Miller Vincent A; Zakowski Maureen F; Rusch Valerie; Kris Mark G; Ladanyi Marc
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
The Journal of molecular diagnostics : JMD 2008;10(3):242-8.
-
2008: Miller Vincent A; Riely Gregory J; Zakowski Maureen F; Li Allan R; Patel Jyoti D; Heelan Robert T; Kris Mark G; Sandler Alan B; Carbone David P; Tsao Anne; Herbst Roy S; Heller Glenn; Ladanyi Marc; Pao William; Johnson David H
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1472-8.
-
2008: Rizvi Naiyer A; Riely Gregory J; Azzoli Christopher G; Miller Vincent A; Ng Kenneth K; Fiore John; Chia Gloria; Brower Martin; Heelan Robert; Hawkins Michael J; Kris Mark G
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):639-43.
-
2008: Miller Vincent A
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Seminars in oncology nursing 2008;24(1):27-33.
-
2008: Janjigian Yelena Y; Miller Vincent A
Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?
Nature clinical practice. Oncology 2008;5(1):10-1.
-
2007: Bean James; Brennan Cameron; Shih Jin-Yuan; Riely Gregory; Viale Agnes; Wang Lu; Chitale Dhananjay; Motoi Noriko; Szoke Janos; Broderick Stephen; Balak Marissa; Chang Wen-Cheng; Yu Chong-Jen; Gazdar Adi; Pass Harvey; Rusch Valerie; Gerald William; Huang Shiu-Feng; Yang Pan-Chyr; Miller Vincent; Ladanyi Marc; Yang Chih-Hsin; Pao William
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(52):20932-7.
-
2007: Herbst Roy S; Davies Angela M; Natale Ronald B; Dang Thao P; Schiller Joan H; Garland Linda L; Miller Vincent A; Mendelson David; Van den Abbeele Annick D; Melenevsky Yulia; de Vries Daniel J; Eberhard David A; Lyons Benjamin; Lutzker Stuart G; Johnson Bruce E
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6175-81.
-
2007: Liu Vincent; White Dorothy A; Zakowski Maureen F; Travis William; Kris Mark G; Ginsberg Michelle S; Miller Vincent A; Azzoli Christopher G
Pulmonary toxicity associated with erlotinib.
Chest 2007;132(3):1042-4.
-
2007: Riely Gregory J; Kris Mark G; Zhao Binsheng; Akhurst Tim; Milton Daniel T; Moore Erin; Tyson Leslie; Pao William; Rizvi Naiyer A; Schwartz Lawrence H; Miller Vincent A
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5150-5.
-
2007: Riely Gregory J; Miller Vincent A
Vascular endothelial growth factor trap in non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4623-7.
-
2007: Milton Daniel T; Riely Gregory J; Azzoli Christopher G; Gomez Jorge E; Heelan Robert T; Kris Mark G; Krug Lee M; Pao William; Pizzo Barbara; Rizvi Naiyer A; Miller Vincent A
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Cancer 2007;110(3):599-605.
-
2007: Azzoli Christopher G; Krug Lee M; Miller Vincent A; Rizvi Naiyer A; Kris Mark G; Dunne Megan; Farmer Amy; Pizzo Barbara; Tyson Leslie; Seeger Teresa; Coleman Barbara; Moore Erin; Lastinger Lauren; Venkatraman Ennapadam; Rudin Charles M
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(7):638-44.
-
2007: Azzoli Christopher G; Krug Lee M; Gomez Jorge; Miller Vincent A; Kris Mark G; Ginsberg Michelle S; Henry Roxanne; Jones Jessica; Tyson Leslie; Dunne Megan; Pizzo Barbara; Farmer Amy; Venkatraman Ennapadam; Steffen Robert; Sirotnak F M
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2692-8.
-
2007: Fury Matthew G; Solit David B; Su Yungpo Bernard; Rosen Neal; Sirotnak F M; Smith Robert P; Azzoli Christopher G; Gomez Jorge E; Miller Vincent A; Kris Mark G; Pizzo Barbara A; Henry Roxanne; Pfister David G; Rizvi Naiyer A
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2007;59(4):467-75.
-
2006: Riely Gregory J; Politi Katerina A; Miller Vincent A; Pao William
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7232-41.
-
2006: Balak Marissa N; Gong Yixuan; Riely Gregory J; Somwar Romel; Li Allan R; Zakowski Maureen F; Chiang Anne; Yang Guangli; Ouerfelli Ouathek; Kris Mark G; Ladanyi Marc; Miller Vincent A; Pao William
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6494-501.
-
2006: Hurria Arti; Fleming Mark T; Baker Sharyn D; Kelly Wm Kevin; Cutchall Katie; Panageas Katherine; Caravelli James; Yeung Henry; Kris Mark G; Gomez Jorge; Miller Vincent A; D'Andrea Gabriella; Scher Howard I; Norton Larry; Hudis Clifford
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
-
2006: Milton Daniel T; Riely Gregory J; Pao William; Miller Vincent A; Kris Mark G; Heelan Robert T
Molecular on/off switch.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4940-2.
-
2006: Milton Daniel T; Azzoli Christopher G; Heelan Robert T; Venkatraman Ennapadam; Gomez Jorge E; Kris Mark G; Krug Lee M; Pao William; Rizvi Naiyer A; Dunne Megan; Miller Vincent A
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Cancer 2006;107(5):1034-41.
-
2006: Pham DuyKhanh; Kris Mark G; Riely Gregory J; Sarkaria Inderpal S; McDonough Tiffani; Chuai Shaokun; Venkatraman Ennapadam S; Miller Vincent A; Ladanyi Marc; Pao William; Wilson Richard K; Singh Bhuvanesh; Rusch Valerie W
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1700-4.
-
2006: Miller Vincent A
Optimizing therapy in previously treated non-small cell lung cancer.
Seminars in oncology 2006;33(1 Suppl 1):S25-31.
-
2006: Riely Gregory J; Pao William; Pham Duykhanh; Li Allan R; Rizvi Naiyer; Venkatraman Ennapadam S; Zakowski Maureen F; Kris Mark G; Ladanyi Marc; Miller Vincent A
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):839-44.
-
2005: Krug Lee M; Miller Vincent A; Patel Jyoti; Crapanzano John; Azzoli Christopher G; Gomez Jorge; Kris Mark G; Heelan Robert T; Pizzo Barbara; Tyson Leslie; Sheehan Christine; Ross Jeffrey S; Venkatraman Ennapadam
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Cancer 2005;104(10):2149-55.
-
2005: Pao William; Ladanyi Marc; Miller Vincent A;
Erlotinib in lung cancer.
The New England journal of medicine 2005;353(16):1739-41; author reply 1739-41.
-
2005: Herbst Roy S; Prager Diane; Hermann Robert; Fehrenbacher Lou; Johnson Bruce E; Sandler Alan; Kris Mark G; Tran Hai T; Klein Pam; Li Xin; Ramies David; Johnson David H; Miller Vincent A;
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5892-9.
-
2005: Eberhard David A; Johnson Bruce E; Amler Lukas C; Goddard Audrey D; Heldens Sherry L; Herbst Roy S; Ince William L; Jänne Pasi A; Januario Thomas; Johnson David H; Klein Pam; Miller Vincent A; Ostland Michael A; Ramies David A; Sebisanovic Dragan; Stinson Jeremy A; Zhang Yu R; Seshagiri Somasekar; Hillan Kenneth J
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5900-9.
-
2005: Milton Daniel T; Miller Vincent A
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer.
Seminars in oncology 2005;32(3):299-314.
-
2005: Omuro Antonio M P; Kris Mark G; Miller Vincent A; Franceschi Enrico; Shah Neelam; Milton Daniel T; Abrey Lauren E
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Cancer 2005;103(11):2344-8.
-
2005: Miller Vincent A; Hirsch Fred R; Johnson David H
Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(14):3288-93.
-
2005: Krug Lee M; Crapanzano John P; Azzoli Christopher G; Miller Vincent A; Rizvi Naiyer; Gomez Jorge; Kris Mark G; Pizzo Barbara; Tyson Leslie; Dunne Megan; Heelan Robert T
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Cancer 2005;103(10):2128-31.
-
2005: Pao William; Miller Vincent A
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2556-68.
-
2005: Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS medicine 2005;2(3):e73.
-
2005: Pao William; Wang Theresa Y; Riely Gregory J; Miller Vincent A; Pan Qiulu; Ladanyi Marc; Zakowski Maureen F; Heelan Robert T; Kris Mark G; Varmus Harold E
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PLoS medicine 2005;2(1):e17.
-
2005: Shah Neelam T; Kris Mark G; Pao William; Tyson Leslie B; Pizzo Barbara M; Heinemann Murk-Hein; Ben-Porat Leah; Sachs Dana L; Heelan Robert T; Miller Vincent A
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):165-74.
-
2005: Laurie Scott A; Miller Vincent A; Grant Stefan C; Kris Mark G; Ng Kenneth K
Phase I study of green tea extract in patients with advanced lung cancer.
Cancer chemotherapy and pharmacology 2005;55(1):33-8.
-
2004: Sarkaria Inderpal S; Pham DuyKhanh; Ghossein Ronald A; Talbot Simon G; Hezel Michael; Dudas Maria E; Ebright Michael I; Chuai Shaokun; Memoli Natalie; Venkatraman Ennapadam S; Miller Vincent A; Kris Mark G; Zakowski Maureen F; Rusch Valerie W; Singh Bhuvanesh
SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2004;78(5):1734-41.
-
2004: Krug Lee M; Ragupathi Govind; Hood Chandra; Kris Mark G; Miller Vincent A; Allen Jennifer R; Keding Stacy J; Danishefsky Samuel J; Gomez Jorge; Tyson Leslie; Pizzo Barbara; Baez Valerie; Livingston Philip O
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6094-100.
-
2004: Pao William; Miller Vincent; Zakowski Maureen; Doherty Jennifer; Politi Katerina; Sarkaria Inderpal; Singh Bhuvanesh; Heelan Robert; Rusch Valerie; Fulton Lucinda; Mardis Elaine; Kupfer Doris; Wilson Richard; Kris Mark; Varmus Harold
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(36):13306-11.
-
2004: Pao William; Miller Vincent A; Venkatraman Ennapadam; Kris Mark G
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Journal of the National Cancer Institute 2004;96(15):1117-9.
-
2004: Sherman Eric J; Rubin David M; Venkatraman Ennapadam; Schwartz Gary K; Miller Vincent A; Radzyner Mark H; Ruchlin Hirsch S; Spriggs David; Pfister David G
Using patients as their own controls for cost evaluation of phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1308-14.
-
2004: Miller Vincent A; Kris Mark G; Shah Neelam; Patel Jyoti; Azzoli Christopher; Gomez Jorge; Krug Lee M; Pao William; Rizvi Naiyer; Pizzo Barbara; Tyson Leslie; Venkatraman Ennapadam; Ben-Porat Leah; Memoli Natalie; Zakowski Maureen; Rusch Valerie; Heelan Robert T
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1103-9.
-
2004: Herbst Roy S; Giaccone Giuseppe; Schiller Joan H; Natale Ronald B; Miller Vincent; Manegold Christian; Scagliotti Giorgio; Rosell Rafael; Oliff Ira; Reeves James A; Wolf Michael K; Krebs Annetta D; Averbuch Steven D; Ochs Judith S; Grous John; Fandi Abderrahim; Johnson David H
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):785-94.
-
2004: Giaccone Giuseppe; Herbst Roy S; Manegold Christian; Scagliotti Giorgio; Rosell Rafael; Miller Vincent; Natale Ronald B; Schiller Joan H; Von Pawel Joachim; Pluzanska Anna; Gatzemeier Ulrich; Grous John; Ochs Judith S; Averbuch Steven D; Wolf Michael K; Rennie Pamela; Fandi Abderrahim; Johnson David H
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):777-84.
-
2004: Krug Lee M; Ragupathi Govind; Ng Kenneth K; Hood Chandra; Jennings Harold J; Guo Zhongwu; Kris Mark G; Miller Vincent; Pizzo Barbara; Tyson Leslie; Baez Valerie; Livingston Philip O
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):916-23.
-
2004: Pao William; Miller Vincent A; Kris Mark G
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Seminars in cancer biology 2004;14(1):33-40.
-
2003: Shah Neelam T; Miller Vincent A
Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Clinical lung cancer 2003;5(3):182-6.
-
2003: She Yuhong; Lee Fei; Chen Jing; Haimovitz-Friedman Adriana; Miller Vincent A; Rusch Valerie R; Kris Mark G; Sirotnak F M
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3773-8.
-
2003: Azzoli Christopher G; Miller Vincent A; Ng Kenneth K; Krug Lee M; Hensley Martee L; O'Reilly Eileen M; Muller Raymond J; Kris Mark G
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.
American journal of clinical oncology 2003;26(3):247-51.
-
2003: Krug Lee M; Azzoli Christopher G; Kris Mark G; Miller Vincent A; Khokhar Nushmia Z; Tong William; Ginsberg Michelle S; Venkatraman Ennapadam; Tyson Leslie; Pizzo Barbara; Baez Valerie; Ng Kenneth K; Sirotnak F M
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2072-8.
-
2003: Miller Vincent A; Johnson David H; Krug Lee M; Pizzo Barbara; Tyson Leslie; Perez Wendy; Krozely Peggy; Sandler Alan; Carbone David; Heelan Robert T; Kris Mark G; Smith Robert; Ochs Judith
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2094-100.
-
2003: Azzoli Christopher G; Miller Vincent A; Ng Kenneth K; Krug Lee M; Spriggs David R; Tong William P; Riedel Elyn R; Kris Mark G
A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2003;51(6):493-8.
-
2003: Patel Jyoti D; Krug Lee M; Azzoli Christopher G; Gomez Jorge; Kris Mark G; Miller Vincent A
Targeting lethal minimal residual disease in small cell lung cancer.
Seminars in oncology 2003;30(1):79-85.
-
2003: Krug Lee M; Miller Vincent A; Filippa Daniel A; Venkatraman Ennapadam; Ng Kenneth K; Kris Mark G
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Lung cancer (Amsterdam, Netherlands) 2003;39(2):139-43.
-
2002: Ebright Michael I; Zakowski Maureen F; Martin Jocelyne; Venkatraman Ennapadam S; Miller Vincent A; Bains Manjit S; Downey Robert J; Korst Robert J; Kris Mark G; Rusch Valerie W
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2002;74(5):1640-6; discussion 1646-7.
-
2002: Downey Robert J; Ng Kenneth K; Kris Mark G; Bains Manjit S; Miller Vincent A; Heelan Robert; Bilsky Mark; Ginsberg Robert; Rusch Valerie W
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.
Lung cancer (Amsterdam, Netherlands) 2002;38(2):193-7.
-
2002: Aghajanian Carol; Soignet Steven; Dizon Don S; Pien Christine S; Adams Julian; Elliott Peter J; Sabbatini Paul; Miller Vincent; Hensley Martee L; Pezzulli Sandra; Canales Christina; Daud Adil; Spriggs David R
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2505-11.
-
2002: Laurie Scott A; Kris Mark G; Portlock Carol S; Rosenzweig Kenneth E; Miller Vincent A; Krug Lee M; Rusch Valerie W
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
Cancer 2002;95(1):119-26.
-
2002: Azzoli Christopher G; Krug Lee M; Miller Vincent A; Kris Mark G; Mass Robert
Trastuzumab in the treatment of non-small cell lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):59-65.
-
2001: Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard J Y; Manegold C
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Seminars in oncology 2001;28(1 Suppl 2):15-21.
-
2000: Sirotnak F M; Zakowski M F; Miller V A; Scher H I; Kris M G
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4885-92.
-
2000: Sirotnak F M; Wendel H G; Bornmann W G; Tong W P; Miller V A; Scher H I; Kris M G
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3705-12.
-
2000: Krug L M; Ng K K; Kris M G; Miller V A; Tong W; Heelan R T; Leon L; Leung D; Kelly J; Grant S C; Sirotnak F M
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3493-8.
-
2000: Fossella F V; DeVore R; Kerr R N; Crawford J; Natale R R; Dunphy F; Kalman L; Miller V; Lee J S; Moore M; Gandara D; Karp D; Vokes E; Kris M; Kim Y; Gamza F; Hammershaimb L
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2354-62.
-
2000: Soignet S L; Miller V A; Pfister D G; Bienvenu B J; Ho R; Parker B A; Amyotte S A; Cato A; Warrell R P
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550).
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1731-5.
-
2000: Miller V A
Trials of vinorelbine and docetaxel in the treatment of advanced non small-cell lung cancer.
Clinical lung cancer 2000;1 Suppl 1():S24-6.
-
2000: Miller V A; Kris M G
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Seminars in oncology 2000;27(2 Suppl 3):3-10.
-
2000: Miller V A; Krug L M; Ng K K; Pizzo B; Perez W; Heelan R T; Kris M G
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1346-50.
-
2000: Miller V A; Ng K K; Krug L M; Perez W; Pizzo B; Heelan R T; Kris M G
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Cancer 2000;88(5):1045-50.
-
2000: Krug L M; Miller V A; Kalemkerian G P; Kraut M J; Ng K K; Heelan R T; Pizzo B A; Perez W; McClean N; Kris M G
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):227-8.
-
2000: Brooks A D; Tong W; Benedetti F; Kaneda Y; Miller V; Warrell R P
Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery.
Cancer chemotherapy and pharmacology 2000;46(4):313-8.
-
1999: Krug L M; Miller V A
Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Seminars in oncology 1999;26(5 Suppl 16):24-6; discussion 41-2.
-
1999: Krug L M; Grant S C; Miller V A; Ng K K; Kris M G
Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
Seminars in oncology 1999;26(5 Suppl 15):55-61.
-
1999: Dickler M N; Ragupathi G; Liu N X; Musselli C; Martino D J; Miller V A; Kris M G; Brezicka F T; Livingston P O; Grant S C
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2773-9.
-
1999: Ng K K; Kris M G; Ginsberg R J; Heelan R T; Pisters K M; Miller V A; Grant S C; Bains M; Rusch V; Rosenzweig K E; Martini N
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
Cancer 1999;86(7):1189-97.
-
1999: Miller V
Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
Seminars in oncology 1999;26(3 Suppl 10):12-4.
-
1999: Rigas J R; Kris M G; Miller V A; Pisters K M; Heelan R T; Grant S C; Fennelly D W; Chou T C; Sirotnak F M
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):601-3.
-
1999: Pizzo B A; Pisters K M; Miller V A; Grant S C; Baltzer L; Hinckley L; Kris M G
Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(1):44-6.
-
1998: Vander Els N J; Miller V
Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.
Chest 1998;114(6):1779-81.
-
1998: Kindler H L; Kris M G; Smith I E; Miller V A; Grant S C; Krebs J B; Ross G A; Slevin M L
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
American journal of clinical oncology 1998;21(5):438-41.
-
1998: Miller V A
Docetaxel in the management of advanced non-small cell lung cancer.
Seminars in oncology 1998;25(3 Suppl 8):15-9.
-
1997: Miller V A; Ng K K; Grant S C; Kindler H; Pizzo B; Heelan R T; von Roemeling R; Kris M G
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1269-71.
-
1997: Miller V A
Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.
Seminars in oncology 1997;24(4 Suppl 14):S14-15-S14-17.
-
1997: Kris M G; Miller V A; Ng K K; Grant S C
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 14):S14-1-S14-4.
-
1997: Miller V A; Benedetti F M; Rigas J R; Verret A L; Pfister D G; Straus D; Kris M G; Crisp M; Heyman R; Loewen G R; Truglia J A; Warrell R P
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):790-5.
-
1997: Miller V A; Rigas J R; Tong W P; Reid J R; Pisters K M; Grant S C; Heelan R T; Kris M G
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(5):415-8.
-
1996: Pisters K M; Tyson L B; Tong W; Fleisher M; Miller V A; Grant S C; Pfister D G; Rigas J R; Densmore C L; Krol G; Heelan R T; Sirotnak F M; Bertino J R; Kris M G
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(11):1819-24.
-
1996: Rigas J R; Miller V A; Zhang Z F; Klimstra D S; Tong W P; Kris M G; Warrell R P
Metabolic phenotypes of retinoic acid and the risk of lung cancer.
Cancer research 1996;56(12):2692-6.
-
1996: Miller V A; Rigas J R; Benedetti F M; Verret A L; Tong W P; Kris M G; Gill G M; Loewen G R; Truglia J A; Ulm E H; Warrell R P
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):471-5.
-
1995: Miller V A; Rigas J R; Pisters K M; Grant S C; Pfister D G; Heelan R T; Kris M G
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
American journal of clinical oncology 1995;18(4):303-6.
-
1995: Miller V A; Reuter V; Scher H I
Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma.
Urology 1995;46(1):111-3.
-
1995: Miller V A; Rigas J R; Grant S C; Pisters K M; Kris M G
New chemotherapeutic agents for non-small cell lung cancer.
Chest 1995;107(6 Suppl):306S-311S.
-
1995: Miller W H; Jakubowski A; Tong W P; Miller V A; Rigas J R; Benedetti F; Gill G M; Truglia J A; Ulm E; Shirley M
9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.
Blood 1995;85(11):3021-7.
-
1995: Kris M G; Pisters K M; Ginsberg R J; Rigas J R; Miller V A; Grant S C; Gralla R J; Heelan R T; Martini N
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2).
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S47-57.
-
1995: Francis P A; Kris M G; Rigas J R; Grant S C; Miller V A
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S163-72.
-
1995: Miller V A; Rigas J R; Francis P A; Grant S C; Pisters K M; Venkatraman E S; Woolley K; Heelan R T; Kris M G
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Cancer 1995;75(4):968-72.
-
1995: Rigas J R; Francis P A; Miller V A; Tong W P; Roistacher N; Kris M G; Orazem J P; Young C W; Warrell R P
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
Cancer chemotherapy and pharmacology 1995;35(6):483-8.
-
1994: Miller V A; Rigas J R; Muindi J R; Tong W P; Venkatraman E; Kris M G; Warrell R P
Modulation of all-trans retinoic acid pharmacokinetics by liarozole.
Cancer chemotherapy and pharmacology 1994;34(6):522-6.
Sign-in to see more
